Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2002 2
2003 1
2004 1
2005 1
2010 1
2011 2
2012 2
2014 1
2015 4
2016 2
2017 1
2018 2
2019 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma.
Eslin D, Zage PE, Bergendahl G, Lewis E, Roberts W, Kraveka J, Mitchell D, Isakoff MS, Rawwas J, Wada RK, Fluchel M, Brown VI, Ginn K, Higgins T, BeeravallyNagulapally A, Dykema K, Hanna G, Ferguson W, Saulnier Sholler GL. Eslin D, et al. Among authors: higgins t. Int J Cancer. 2023 Sep 1;153(5):1026-1034. doi: 10.1002/ijc.34569. Epub 2023 May 29. Int J Cancer. 2023. PMID: 37246577 Clinical Trial.
Step-by-step use of hemostatic powder: treatment of a bleeding GI stromal tumor.
Storm AC, Sawas T, Higgins T, Bruining DH, Leggett CL, Buttar NS, Wong Kee Song LM, Abu Dayyeh BK. Storm AC, et al. Among authors: higgins t. VideoGIE. 2018 Nov 23;4(1):5-6. doi: 10.1016/j.vgie.2018.10.003. eCollection 2019 Jan. VideoGIE. 2018. PMID: 30623148 Free PMC article. No abstract available.
A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma.
Saulnier Sholler GL, Bergendahl GM, Brard L, Singh AP, Heath BW, Bingham PM, Ashikaga T, Kamen BA, Homans AC, Slavik MA, Lenox SR, Higgins TJ, Ferguson WS. Saulnier Sholler GL, et al. Among authors: higgins tj. J Pediatr Hematol Oncol. 2011 Jan;33(1):25-30. doi: 10.1097/MPH.0b013e3181f47061. J Pediatr Hematol Oncol. 2011. PMID: 21063221 Clinical Trial.
A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
Saulnier Sholler GL, Gerner EW, Bergendahl G, MacArthur RB, VanderWerff A, Ashikaga T, Bond JP, Ferguson W, Roberts W, Wada RK, Eslin D, Kraveka JM, Kaplan J, Mitchell D, Parikh NS, Neville K, Sender L, Higgins T, Kawakita M, Hiramatsu K, Moriya SS, Bachmann AS. Saulnier Sholler GL, et al. Among authors: higgins t. PLoS One. 2015 May 27;10(5):e0127246. doi: 10.1371/journal.pone.0127246. eCollection 2015. PLoS One. 2015. PMID: 26018967 Free PMC article. Clinical Trial.
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma.
Mitchell D, Bergendahl G, Ferguson W, Roberts W, Higgins T, Ashikaga T, DeSarno M, Kaplan J, Kraveka J, Eslin D, Werff AV, Hanna GK, Sholler GL. Mitchell D, et al. Among authors: higgins t. Pediatr Blood Cancer. 2016 Jan;63(1):39-46. doi: 10.1002/pbc.25687. Epub 2015 Jul 31. Pediatr Blood Cancer. 2016. PMID: 26235333 Clinical Trial.
20 results